Insight Molecular Diagnostics Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Insight Molecular Diagnostics Inc. (IMDX) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $2.34 million as of 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2025-11-10
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $2.34M.
- 2025-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $2.52M.
- 2025-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $2.59M.
- 2024-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $2.76M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | Finance Lease, Right-of-Use Asset, after Accumulated Amortization as first filed |
|---|---|---|
| 2025-09-30 | $2.34M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $2.52M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $2.59M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $2.76M 10-Q · filed 2025-11-10 | |
| 2024-09-30 | $3.00M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $2.59M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $2.20M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $1.64M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $1.76M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $1.89M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $2.02M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $2.18M 10-K · filed 2024-04-16 | $2.09M 10-K · filed 2023-04-12 |
| 2022-09-30 | $2.34M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $2.49M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $2.64M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $2.78M 10-K · filed 2023-04-12 | |
| 2021-09-30 | $2.92M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $2.95M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $311.00K 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $3.26M 10-K · filed 2022-03-11 | $343.00K 10-K · filed 2021-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |